Success Metrics

Active Trials

1(20%)

Phase Distribution

Ph phase_1

20%

Ph phase_2

40%

Ph phase_3

40%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution5 total trials

Phase 1Safety & dosage

1(20.0%)

Phase 2Efficacy & side effects

2(40.0%)

Phase 3Large-scale testing

2(40.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

0.0%

0 of 0 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Active(5)

Detailed Status

Not yet recruiting4

Recruiting1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

N/A

Most Advanced

Phase 3

Trials by Phase

Phase 11 (20.0%)

Phase 22 (40.0%)

Phase 32 (40.0%)

Trials by Status

not_yet_recruiting480%

recruiting120%

Recent Activity

1 active trials

Showing 5 of 5

not_yet_recruitingphase_3

SYS6002 vs Chemotherapy in Patients With Locally Advanced or Metastatic Urothelial Carcinoma

NCT07526792

not_yet_recruitingphase_2

SYS6002 vs PADCEV in Patients With Advanced Urothelial Carcinoma

NCT07374549

recruitingphase_1

A Study of Sirolimus (Albumin-Bound) in Combination With Different ADCs Treatment of Advanced Solid Tumors

NCT07241936

not_yet_recruitingphase_3

SYS6002 vs Chemotherapy in Recurrent or Metastatic Cervical Cancer

NCT07230626

not_yet_recruitingphase_2

SYS6002 Plus JMT101 and Enlonstobart Injection in Participants With HNSCC

NCT06989671

Clinical Trials (5)

Showing 5 of 5 trials

NCT07526792Phase 3

SYS6002 vs Chemotherapy in Patients With Locally Advanced or Metastatic Urothelial Carcinoma

Not Yet Recruiting

NCT07374549Phase 2

SYS6002 vs PADCEV in Patients With Advanced Urothelial Carcinoma

Not Yet Recruiting

NCT07241936Phase 1

A Study of Sirolimus (Albumin-Bound) in Combination With Different ADCs Treatment of Advanced Solid Tumors

Recruiting

NCT07230626Phase 3

SYS6002 vs Chemotherapy in Recurrent or Metastatic Cervical Cancer

Not Yet Recruiting

NCT06989671Phase 2

SYS6002 Plus JMT101 and Enlonstobart Injection in Participants With HNSCC

Not Yet Recruiting

All 5 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 5